Can the cell and gene therapy field create industry consensus on a more detailed level? In this Insight Article, Jorgen Magnus, Strategic Program Lead of Cell and Gene Therapy at Bayer, highlights the promise of process mapping for reaching a harmonised approach to development and manufacturing standards.

This commentary article looks at the future of AAV engineering and cell therapy analytics, with exclusive insights from Sanofi and Genentech.

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our October Discussion Group addressing ‘Challenges and Opportunities in Viral Vector-Based Gene Therapy’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.

Arun Srivastava of the University of Florida’s takes us through the history of the AAV Vector development for Human Gene Therapy and analyses the critical role of his institution’s Division of Cellular and Molecular Therapy in the optimising and discovery of Next Generation AAVs.

Presented by Erin Cross, Associate Director of Whole Genome R&D, KromaTid & Chris Tompkins, Chief Technology Officer, KromaTid

In Conversation With Volker Huppert, Chief Development Officer at Glycostem Therapeutics

Video Interview | ARUN SRIVASTAVA, George H. Kitzman Professor of Genetics, Chief, Division of Cellular and Molecular Therapy, University of Florida College of Medicine

Hosted by Ta-Chun Hang, Senior Scientist, bluebird bio

Jeffrey Galvin, Chief Executive Officer & Founder of American Gene Technologies

Paul Lammers, President & Chief Executive Officer, Triumvira Immunologics